,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3009 boulevard de la Concorde East,Suite 102,Laval,QC,H7E 2B5,Canada,450-687-2262,https://www.acastipharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Mr. Prashant  Kohli', 'age': 50, 'title': 'Chief Exec. Officer', 'yearBorn': 1972, 'fiscalYear': 2023, 'totalPay': 358410, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.01,1.952,1.93,2.0699,2.01,1.952,1.93,2.0699,0.0,1.490318,-4.902439,6616,6616,26375,8720,8720,1.99,2.01,900,900,14970540,1.92,5.04,2.3324,2.9615,0.0,0.0,USD,-6597453,0.0,5198131,7448030,18852,18365,1690761600,1693440000,0.0025,0.11414,0.0038100001,1.38,0.0032,7448030,8.609,0.2334766,1680220800,1711843200,1688083200,-41928000,-5.63,-0.41,1:6,1688947200,0.401,-0.54109585,0.14113986,NCM,EQUITY,ACST,ACST,"Acasti Pharma, Inc.",Acasti Pharma Inc.,1328625000,America/New_York,EDT,b85d19b3-5615-3119-8c13-5a148ac836a8,finmb_47663822,-14400000,2.01,1.96,1.96,1.96,1.96,1.0,strong_buy,1,21648000,2.907,-16470000,80000,11.437,12.01,0.125,-0.103769995,-0.49792,-9177250,-16727000,0.0,0.0,0.0,USD,
1,3009 boulevard de la Concorde East,Suite 102,Laval,QC,H7E 2B5,Canada,450-687-2262,https://www.acastipharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Mr. Brian D. Ford CPA, CA', 'age': 63, 'title': 'Interim Chief Financial Officer', 'yearBorn': 1959, 'fiscalYear': 2023, 'totalPay': 379346, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.01,1.952,1.93,2.0699,2.01,1.952,1.93,2.0699,0.0,1.490318,-4.902439,6616,6616,26375,8720,8720,1.99,2.01,900,900,14970540,1.92,5.04,2.3324,2.9615,0.0,0.0,USD,-6597453,0.0,5198131,7448030,18852,18365,1690761600,1693440000,0.0025,0.11414,0.0038100001,1.38,0.0032,7448030,8.609,0.2334766,1680220800,1711843200,1688083200,-41928000,-5.63,-0.41,1:6,1688947200,0.401,-0.54109585,0.14113986,NCM,EQUITY,ACST,ACST,"Acasti Pharma, Inc.",Acasti Pharma Inc.,1328625000,America/New_York,EDT,b85d19b3-5615-3119-8c13-5a148ac836a8,finmb_47663822,-14400000,2.01,1.96,1.96,1.96,1.96,1.0,strong_buy,1,21648000,2.907,-16470000,80000,11.437,12.01,0.125,-0.103769995,-0.49792,-9177250,-16727000,0.0,0.0,0.0,USD,
2,3009 boulevard de la Concorde East,Suite 102,Laval,QC,H7E 2B5,Canada,450-687-2262,https://www.acastipharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Dr. R. Loch MacDonald M.D., Ph.D.', 'age': 60, 'title': 'Member of Scientific Advisory Board & Chief Medical Officer', 'yearBorn': 1962, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.01,1.952,1.93,2.0699,2.01,1.952,1.93,2.0699,0.0,1.490318,-4.902439,6616,6616,26375,8720,8720,1.99,2.01,900,900,14970540,1.92,5.04,2.3324,2.9615,0.0,0.0,USD,-6597453,0.0,5198131,7448030,18852,18365,1690761600,1693440000,0.0025,0.11414,0.0038100001,1.38,0.0032,7448030,8.609,0.2334766,1680220800,1711843200,1688083200,-41928000,-5.63,-0.41,1:6,1688947200,0.401,-0.54109585,0.14113986,NCM,EQUITY,ACST,ACST,"Acasti Pharma, Inc.",Acasti Pharma Inc.,1328625000,America/New_York,EDT,b85d19b3-5615-3119-8c13-5a148ac836a8,finmb_47663822,-14400000,2.01,1.96,1.96,1.96,1.96,1.0,strong_buy,1,21648000,2.907,-16470000,80000,11.437,12.01,0.125,-0.103769995,-0.49792,-9177250,-16727000,0.0,0.0,0.0,USD,
3,3009 boulevard de la Concorde East,Suite 102,Laval,QC,H7E 2B5,Canada,450-687-2262,https://www.acastipharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': 'Mr. Amresh  Kumar Ph.D.', 'age': 42, 'title': 'VP of Program Management', 'yearBorn': 1980, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.01,1.952,1.93,2.0699,2.01,1.952,1.93,2.0699,0.0,1.490318,-4.902439,6616,6616,26375,8720,8720,1.99,2.01,900,900,14970540,1.92,5.04,2.3324,2.9615,0.0,0.0,USD,-6597453,0.0,5198131,7448030,18852,18365,1690761600,1693440000,0.0025,0.11414,0.0038100001,1.38,0.0032,7448030,8.609,0.2334766,1680220800,1711843200,1688083200,-41928000,-5.63,-0.41,1:6,1688947200,0.401,-0.54109585,0.14113986,NCM,EQUITY,ACST,ACST,"Acasti Pharma, Inc.",Acasti Pharma Inc.,1328625000,America/New_York,EDT,b85d19b3-5615-3119-8c13-5a148ac836a8,finmb_47663822,-14400000,2.01,1.96,1.96,1.96,1.96,1.0,strong_buy,1,21648000,2.907,-16470000,80000,11.437,12.01,0.125,-0.103769995,-0.49792,-9177250,-16727000,0.0,0.0,0.0,USD,
4,3009 boulevard de la Concorde East,Suite 102,Laval,QC,H7E 2B5,Canada,450-687-2262,https://www.acastipharma.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","{'maxAge': 1, 'name': ""Ms. Carrie  D'Andrea"", 'age': 50, 'title': 'VP of Clinical Operations', 'yearBorn': 1972, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,2.01,1.952,1.93,2.0699,2.01,1.952,1.93,2.0699,0.0,1.490318,-4.902439,6616,6616,26375,8720,8720,1.99,2.01,900,900,14970540,1.92,5.04,2.3324,2.9615,0.0,0.0,USD,-6597453,0.0,5198131,7448030,18852,18365,1690761600,1693440000,0.0025,0.11414,0.0038100001,1.38,0.0032,7448030,8.609,0.2334766,1680220800,1711843200,1688083200,-41928000,-5.63,-0.41,1:6,1688947200,0.401,-0.54109585,0.14113986,NCM,EQUITY,ACST,ACST,"Acasti Pharma, Inc.",Acasti Pharma Inc.,1328625000,America/New_York,EDT,b85d19b3-5615-3119-8c13-5a148ac836a8,finmb_47663822,-14400000,2.01,1.96,1.96,1.96,1.96,1.0,strong_buy,1,21648000,2.907,-16470000,80000,11.437,12.01,0.125,-0.103769995,-0.49792,-9177250,-16727000,0.0,0.0,0.0,USD,
